Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin

Combinations of platinum-based compounds with doxorubicin in free and/or in liposomal form for improved safety are currently being evaluated in the neoadjuvant setting on patients with advanced triple-negative breast cancer (TNBC). However, TNBC may likely be driven by chemotherapy-resistant cells....

Descripción completa

Detalles Bibliográficos
Autores principales: Salerno, Dominick, Sofou, Stavroula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540483/
https://www.ncbi.nlm.nih.gov/pubmed/34681259
http://dx.doi.org/10.3390/ph14101035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540483/
https://www.ncbi.nlm.nih.gov/pubmed/34681259
http://dx.doi.org/10.3390/ph14101035

Ejemplares similares